News
Celon Pharma S.A. is a participant of the conference “Prespective Solutions for Biotechnological Medicine”
On June 20-22, 2022, Celon Pharma will take part in the international conference “Prespective Solutions for Biotechnological Medicine”, the main assumption of which will be to focus attention on the need to improve the methodology of allocation and accounting for European funds allocated to the development of research and innovative implementations, on the initiative ofRead more »
Celon Pharma S.A. Bio Forum Central European
On May 25-26, 2022, the 20th biotechnology sector fair – CEBioForum 2022 – will take place in Warsaw.As part of the conference, the President of the Management Board of Celon Pharma, Maciej Wieczorek, will take part in a discussion panel entitled “Development and funding of biotech companies”. In addition, Celon Pharma took the patronage ofRead more »
Celon Pharma S.A. at the “International Conference on Drug Sciences, ACCORD”
On May 26-28, 2022, the conference “International Conference on Drug Sciences, ACCORD” will be held. Its aim is to develop synergies between research and activities in different fields that contribute to the development of the drug. The conference will be accompanied by exhibitions of manufacturers and distributors of scientific instrumentation and laboratory equipment. On theRead more »
Current report No. 7/2022 – Assimilation of the Company’s 30,000 C-series shares and their introduction to stock exchange trading
Date prepared: 04/05/2022 Legal basis: Article 56 subs. 1 point 2 of the Act on Public Offering – current and periodical information Content of the report: The Management Board of Celon Pharma S.A. (the “Company”) hereby informs that on April 5, 2022 the Management Board of the Warsaw Stock Exchange (“WSE”) adopted a resolution inRead more »
Jefferies initiates analytical coverage of Celon Pharma
Jefferies initiates analytical coverage of Celon Pharma, with the recommendation: Buy and the target price of PLN 37.50. The report is available to Jefferies customers. Lucy Codrington, MBChB | Equity Analyst, European HealthcareJefferies International Ltd | 100 Bishopsgate | London | EC2N 4JL |[email protected]
March 11, 2022 – Current report no. 6/2022 – Wydanie 30.000 akcji serii C w ramach warunkowego podwyższenia kapitału zakładowego
The Management Board of Celon Pharma S.A. (“Company”) informs that on March 11, 2022, 30,000 series C shares of the Company, with a nominal value of PLN 0.10 each, were entered in the securities accounts of the entitled persons, as part of the conditional increase of the Company’s share capital (“Shares”). The Shares were takenRead more »
February 21, 2022 – Current Report no. 5/2022 – Conclusion of a license purchase agreement
Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information.Date: February 21, 2022, time: 22:18 p.m.The Management Board of Celon Pharma S.A. (“Company”) informs that on February 20, 2022, it learned about the conclusion of an agreement with the Salk Institute for Biological Studies (“Salk”) on the purchase of a
Legal basis: Article 56 section 1 point 2 Act on Public Offering – current and periodic information.Date: February 16, 2022.The abbreviated name of the issuer CELON PHARMA S.A.Subject: The KDPW statement on concluding an agreement on the registration of the Company’s series C shares The Management Board of Celon Pharma SA (the “Company”) hereby informsRead more » Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Date: January 21, 2022, time: 05:08 p.m. The Management Board of Celon Pharma S.A. (“Company”) announces that on January 21, 2022, it learned about the inclusion of the first patient in the Phase II clinical trial of CPL’280, a second-generationRead more »
February 16, 2022 – Current Report No. 4/2022 – The KDPW statement on concluding an agreement on the registration of the Company’s series C shares
January 21, 2022 – Current Report No. 3/2022 – Phase II clinical trial of CPL’280 in treatment of type 2 diabetes commenced